Atrás
Precio Helix BioMedix Inc (HXBM)
Gráfico del Precio de Acciones HXBM
HXBM Ganando
Helix BioMedix Inc
$2.7
0%
$0
Al cierre: Feb 13, 16:00:00 GMT-5
$2.7
0%
$0
Mercado Posterior: Feb 13, 20:00:00 GMT-5
Sin datos aúnEarnings FAQ
¿Cómo se comparó el EPS reciente de HXBM con las expectativas?
¿Cómo fue el desempeño de los ingresos de Helix BioMedix Inc HXBM en el último trimestre?
¿Cuál es la estimación de ingresos para Helix BioMedix Inc?
¿Cuál es la puntuación de calidad de ganancias de Helix BioMedix Inc?
¿Cuándo informa Helix BioMedix Inc sus ganancias?
¿Cuáles son las ganancias esperadas de Helix BioMedix Inc?
¿Superó Helix BioMedix Inc las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
$2.7
Precio de apertura
$2.7
Rango del día
$2.7 - $2.7
Rango de 52 semanas
$1.75 - $7.19
Volumen
200
Volumen promedio
42
EPS (TTM)
-15.60
Rendimiento de dividendos
--
Cap. de mercado
$621.0K
¿Qué es HXBM?
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is in the preclinical stage of development and intends to file for orphan drug designation prior to entering the clinical development pathway. Its legacy business consists of an proprietary library of patented bioactive peptides. Its lead drug development candidate, HB4208, is a polypeptide DNA deoxyribonucleic (DNA) damage response (DDR) enzyme for topical treatment of the rare genetic disorder (orphan disease) XP. Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. The company is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. The company is also engaged in the treatment of skin conditions.
Características
© 2026 Finture Development Limited. Todos los derechos reservados.